Thursday, July 23, 2026

TGA / PMDA / NMPA · Asia-Pacific

fluticasone furoate — TGA / PMDA / NMPA regulatory status

fluticasone furoate (ARNUITY ELLIPTA) regulatory status in the Asia-Pacific is tracked from public TGA / PMDA / NMPA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: TGA approved.

Status snapshot

Status
TGA approved
Brand
ARNUITY ELLIPTA
Originator
GlaxoSmithKline
Mechanism
Glucocorticoid receptor agonist
Target
Glucocorticoid receptor
Structured fields
7

Sponsor / originator context: GlaxoSmithKline. Pipeline programs and exclusivity signals below are joined from ClinicalTrials.gov-linked projects and USPTO/EPO patent rows associated with this INN.

Pharmacology context used for competitive intelligence: Glucocorticoid receptor agonist. Target: Glucocorticoid receptor. This page is a status aggregation for professional reference — not prescribing advice.

Regional decision snapshot — TGA: approved.

Linked evidence on this spoke: 1 published clinical program and 0 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.

Regulatory timeline

Regulator Region Status Date Source
TGA Australia approved Evidence

Linked clinical programs

Program Phase Sponsor NCT
Fluticasone furoate Phase 3 GSK Glaxo Smith NCT01622231

Related hubs

FAQ

What is the TGA / PMDA / NMPA approval status of fluticasone furoate?

fluticasone furoate currently shows TGA approved in our Asia-Pacific regulatory index. Confirm on the official TGA / PMDA / NMPA label or EPAR before clinical or commercial use.

Where does NovaPharmaNews get fluticasone furoate regulatory data?

Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.

How many clinical programs are linked to fluticasone furoate?

This spoke lists 1 published program associated with fluticasone furoate in our pipeline index.